A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

• Status: Completed
• Trial end date: 2016-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• Participants identified by the investigator as a candidate for treatment for asthma with omalizumab

• Confirmation of access to omalizumab through insurance or other source of funding

Exclusion Criteria:

• Enrollment in any other concurrent clinical trial or observational study

• Participants for whom omalizumab treatment is contraindicated

• Participants who had a prior allergic reaction to omalizumab or its excipients

• Participants treated with omalizumab within the previous year

• Participants who received an experimental drug as part of another study within 3 months of enrollment